Back to top
more

Loncar China BioPharma ETF: (CHNA)

(Delayed Data from NASDAQ) As of May 14, 2021 12:40 PM ET

 Add to portfolio

$41.50 USD

41.5
1,461

+1.67 (1.60%)

Volume: 1,461

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

ETF Quote Details

Previous Close 39.83
Open 41.20
Bid 37.50
Ask 41.62
Day Low-High 40.66-41.51
52wk Low-High 25.17-42.46
Volume 1,461
NAV (month end) 41.28
Premium (+)/Discount (-) (month end)-1.45

Zacks Premium Research for CHNA

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

Hold 3
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

NA
ETF Snapshot

ETF Expense Ratio

Expense Ratio 0.79%
Dividend (Yield) $0.15 (0.39%)
Issuer LONCAR INVESTMENTS

Benchmark for CHNA

LONCAR CHINA BIOPHARMA INDEX

The Loncar China BioPharma Index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of pharmaceutical and biotech related industries from China.

Fund Summary for CHNA

LONCAR CHINA BIOPHARMA ETF

The Loncar China BioPharma ETF seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index.